HEDIS®1: Statin Therapy for Patients with Diabetes (SPD) Description of the measure Frequently asked questions Patients with diabetes should be started My patient has an LDL at treatment goal on statin therapy for primary prevention and does not need statin therapy. What of cardiovascular disease events and should I do? This measure is based on mortality per American Heart Association recommendations for the majority of (ACC/AHA) 2019 Blood Cholesterol diabetic patients. However, providers are guidelines2. This measure applies to encouraged to follow the plan they feel is patients who meet all of the following: clinically appropriate for their patients. ❑ Are 40-75 years of age Tips for best practice ❑ Have a diagnosis of diabetes or two ❑ Diabetes as per AHA guidelines fills of a diabetes medication ❑ If not appropriate (see exclusions) ❑ Do not have a diagnosis of please document the reason for non- atherosclerotic cardiovascular disease indication in the medical record (ASCVD) ❑ Patients with a history of statin- Exclusion(s) associated myopathy may better Patients with history of MI, CABG, IVD, tolerate medications with a lower PCI, or other revascularization are incidence of muscle-related adverse recommended statin therapy, but are not events (e.g. Pravastatin or included in this measure. If the below Fluvastatin)3 contraindications were diagnosed during ❑ Encourage patient adherence by the current year or year prior, please prescribing 90-day supply document in the medical record: Description Prescription of statin (mg) ❑ ESRD Low Simvastatin 10 Fluvastatin 20-40 ❑ Cirrhosis intensity Pravastatin 10-20 Pitavastatin 1 Lovastatin 20 ❑ Myalgia, myositis, myopathy or Moderate Atorvastatin 10-20 Lovastatin 40 rhabdomyolysis during the current intensity Rosuvastatin 5-10 Fluvastatin XL 80 year Simvastatin 20-40 Fluvastatin 40 BID ❑ Pregnancy Pravastatin 40-80 Pitavastatin 2-4 ❑ In vitro fertilization ❑ Prescription for clomiphene High Atorvastatin 40-80 Rosuvastatin 20-40 ❑ Palliative care intensity 1 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA) 2 https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/03/07/16/00/2019-acc-aha-guideline-on-primary-prevention-gl-prevention 3 Bruckert, et al. Cardiovasc Drug Ther, 2005 MCC-ALL-PRV-16332-20